The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

Purpose

The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)

Condition

  • Methamphetamine Use Disorder

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Meet DSM-5 criteria for MA use disorder - Be fluent in English and able to understand the consent form

Exclusion Criteria

  • Have an alcohol use disorder or report binge drinking (>7 drinks for women and >14 drinks for men) - Have a greater than mild substance use disorder on any other illicit substance - Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy) - Are currently taking medications with known drug interactions with SUVO (e.g., MAO inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and any sedative) - Are pregnant or breast feeding - BMI > 30 (women only) - Have a current DSM-5 psychiatric disorder or neurological disease requiring on-going treatment that would make participation unsafe - Have history of seizure disorder - Have a head injury with loss of consciousness in the last 5 years

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Basic Science
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
1 week Placebo then 1 week SUVO 		After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication
  • Drug: SUVO
    Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
  • Drug: Placebo
    Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
Experimental
1 week SUVO then 1 week Placebo 		After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo
  • Drug: SUVO
    Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
  • Drug: Placebo
    Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.

Recruiting Locations

The University of Texas Health Science Center at Houston
Houston, Texas 77030
Contact:
Heather Webber, PhD
713-486-2723
Heather.E.Webber@uth.tmc.edu

More Details

Status
Recruiting
Sponsor
The University of Texas Health Science Center, Houston

Study Contact

Heather Webber, PhD
713-486-2723
Heather.E.Webber@uth.tmc.edu